Multiple Myeloma & Lymphoma Summit

Park City, UT US
May 20, 2023

This CME-accredited activity Multiple Myeloma & Lymphoma Summit features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to, CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

 

Platinum Sponsor 

Janssen Biotech, Inc.

Bronze Sponsor

Legend Biotech

Target Audience

  • Practicing medical oncologists/hematologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Hotel Information

A limited number of rooms have been reserved for the attendees of this conference at the DoubleTree by Hilton Park City – The Yarrow at a discounted rate of $129/night.

Reserve your room at the following link by the cutoff date Tuesday, April 19, 2023, to receive the discounted rate: https://group.doubletree.com/8pxhfa

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for induction, autologous transplantation, and maintenance therapy for patients with newly diagnosed multiple myeloma
  • Outline efficacy and toxicities of monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with relapsed and refractory multiple myeloma
  • Review CAR-T, bispecific antibodies, and antibody drug conjugates in management of DLBCL patients
  • Apply an individualized treatment plan for patients with early/advanced stage cHL and T cell lymphomas 
  • List indications and toxicity profile of novel targeted agents in management of indolent lymphomas including CLL, FL, MCL
  • Review the indications for the treatment of Waldenström Macroglobulinemia and current therapeutic strategies

 

Course summary
Available credit: 
  • 5.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.25 Contact Hours.
Course opens: 
12/01/2022
Course expires: 
11/15/2023
Event starts: 
05/20/2023 - 8:00am PDT
Event ends: 
05/20/2023 - 4:15pm PDT
Cost:
$200.00
Add to calendar: 

Conference Co-Chairs: Dr. Harsh Shah & Dr. Douglas Sborov

May 20, 2023

 

07:00 AM - 07:45 AM          Breakfast, Exhibits, and Registration

07:50 AM – 08:00 AM          Welcome remarks

08:00 AM - 09:15 AM          Session 1: Newly Diagnosed Multiple Myeloma: How Much and for How Long?

08:00 AM - 08:20 AM          Transplant Ineligible Disease: Is there a role for proteasome inhibitors? - Douglas Sborov, MD MS

08:20 AM – 08:40 AM          The Role of Quadruplet Therapy for All Newly Diagnosed Patients - Ghulam (Manni) Mohyuddin, MD

08:40 AM - 09:00 AM          Maintenance Therapy: Drug Choice and Duration of Treatment - Craig Hofmeister, MD, MPH

09:00 AM - 09:15 AM          Case-based panel discussion with Dane Osborn, MD

09:15 AM - 10:30 AM         Session 2: Relapsed and Refractory Multiple Myeloma and Emerging Immunotherapies

09:15 AM - 09:35 AM          What to Use and When: Drug Sequencing in Relapsed and Refractory Multiple Myeloma - Amandeep Godara, MD

09:35 AM - 09:55 AM          CAR-T and T-cell Redirecting Bispecific Antibodies in Multiple Myeloma - Brian McClune, DO

09:55 AM - 10:15 AM          New and Exciting Therapeutics: An ASH Update! - Craig Hofmeister, MD, MPH

10:15 AM - 10:30 AM          Case-based panel discussion with Gliceida Galarza Fortuna, MD

10:30 AM - 10:45 AM          Break & Exhibit Visits

10:45 AM - 12:20 PM          Session 3: Management of Patients with Indolent Lymphomas with Immunotherapy and Targeted Agents

10:45 AM - 11:05 AM          Treatment Updates in Waldenström Macroglobulinemia -  Amandeep Godara, MD

11:05 AM - 11:25 AM          Frontline management of patients with CLL in the era of targeted agents - Deborah Stephens, DO

11:25 AM - 11:45 AM          Updates in the management of patients with MCL in frontline and relapsed/refractory setting - Daniel A. Ermann, MD

11:45 AM - 12:05 PM          Emerging role of immunotherapy and targeted agents in the management of FL (including CAR T) - Wayne Ormsby, MD

12:05 PM - 12:20 PM          Case-based panel discussion with Taylor Kujawa, PharmD

12:20 PM - 01:30 PM          Lunch  & Exhibit Viewing

12:30 PM - 1:15 PM          Product theater sponsored by AstraZeneca - Use of a Targeted Agent For Previously Untreated or R/R CLL - Dr. Callie Coombs - this non-CME activity will take place in the Ivers Room

01:30 PM - 02:45 PM          Session 4: Management of Patients with Aggressive Lymphomas with Immunotherapy and Targeted Agents

01:30 PM - 01:50 PM          Frontline treatment of patients with DLBCL - Lindsey Fitzgerald, MD

01:50 PM - 02:10 PM          CAR-T updates in DLBCL - Indumathy Varadarajan, MBBS

02:10 PM - 02:30 PM          The role of other immunotherapies (Bi-specifics, ADCs, ASCT) in DLBCL - Dipenkumar Modi, MD

02:30 PM - 02:45 PM          Case-based panel discussion with Daniel A. Ermann, MD

02:45 PM - 04:00 PM         Session 5: Management of Hodgkin Lymphoma and T-cell Lymphomas

02:45 PM - 03:05 PM          Frontline Management of patients with early stage and Advanced cHL - Boyu Hu, MD

03:05 PM - 03:25 PM          Immunotherapy in relapsed/refractory cHL - Harsh Shah, DO

03:25 PM - 03:45 PM          Updates in cutaneous T cell Lymphomas - Ahmad Halwani, MD

03:45 PM - 04:00 PM          Case-based panel discussion with Charlotte Wagner, PharmD

04:00 PM                            Concluding remarks

DoubleTree by Hilton Park City – The Yarrow
1800 Park Ave
Park City, UT 84060
United States

A limited number of rooms have been reserved for the attendees of this conference at the DoubleTree by Hilton Park City – The Yarrow at a discounted rate of $129/night.

Reserve your room at the following link by Tuesday, April 19, 2023, to receive the discounted rate: https://group.doubletree.com/8pxhfa

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Douglas Sborov, MD MS

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Sanofi;.

Harsh Shah, D.O.

has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with BeiGene;.
Speaker/Topic Presenter(s)

Daniel Ermann, Medical Doctor

has no relevant financial relationships to disclose at this time.

Lindsey Fitzgerald, MD

has no relevant financial relationships to disclose at this time.

Gliceida Galarza Fortuna

has no relevant financial relationships to disclose at this time.

Amandeep Godara, MD

has no relevant financial relationships to disclose at this time.

Ahmad Halwani, M.D.

has a financial relationship (Grant Or Contract) with Abbvie/Pharmacyclics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Bayer;.

Craig Hofmeister, MD

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Janssen;.

Boyu Hu

has a financial relationship (Other) with TG Therapeutics;.
has a financial relationship (Other) with Bristol Meyer Squibb;.
has a financial relationship (Grant Or Contract) with Morphosys Ag;.
has a financial relationship (Other) with MJH Life Sciences;.
has a financial relationship (Grant Or Contract) with CRISPR Therapeutics;.
has a financial relationship (Grant Or Contract) with Caribou Biosciences;.
has a financial relationship (Other) with OncLive;.
has a financial relationship (Grant Or Contract) with Celgene/BMS;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with ADC Therapeutics;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with Repare Therapeutics;.

Taylor Kujawa, PharmD

has no relevant financial relationships to disclose at this time.

Brian McClune, DO

has no relevant financial relationships to disclose at this time.

Dipenkumar Modi, M.D.

has a financial relationship (Intellectual Property Other) with AstraZeneca;.
has a financial relationship (Intellectual Property Other) with Karyopharm;.
has a financial relationship (Intellectual Property Other) with ADC Therapeutics;.
has a financial relationship (Intellectual Property Other) with Beigene;.
has a financial relationship (Intellectual Property Other) with Genentech;.
has a financial relationship (Intellectual Property Other) with Genentech;.
has a financial relationship (Intellectual Property Other) with Seagen;.
has a financial relationship (Intellectual Property Other) with AstraZeneca;.

Ghulam Rehman Mohyuddin, MD

has no relevant financial relationships to disclose at this time.

Wayne Ormsby, MD

has no relevant financial relationships to disclose at this time.

Dane Osborn, MD

has no relevant financial relationships to disclose at this time.

Douglas Sborov, MD MS

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.

Harsh Shah, D.O.

has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with BeiGene;.

Deborah Stephens, DO

has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Celegene;.
has a financial relationship (Independent contractor) with Innate Pharma;.
has a financial relationship (Independent contractor) with CSL Behring;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Karyopharm, Novartis, Arqule, Mingsight, JUNO, Newave;.

Indumathy Varadarajan, MBBS

has a financial relationship (Professional Services) with Kite;.

Charlotte Wagner, PharmD, BCOP

has no relevant financial relationships to disclose at this time.
Moderator(s)

Douglas Sborov, MD MS

has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Abbvie;.

Harsh Shah, D.O.

has a financial relationship (Grant Or Contract) with BeiGene;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.

Available Credit

  • 5.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.25 Contact Hours.

 

Price

Cost:
$200.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $200

Non-physician HCP (non-industry) - $75

Industry representatives - $850 (early-bird rate if registered on or before 5/8/23), $1050 starting on 5/9/23; $1250 on-site

 

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.